Skip to main content

Advertisement

Table 3 Overview of the main controller therapies used for the treatment of asthma.

From: Asthma

  Usual Adult Dose Usual Pediatric Dose
ICSs
Beclomethasone (Qvar, generics) MDI: 100–800 µg/day, divided bid MDI: 100-200 μg/day, divided bid (for children 5-11 years)
Budesonide (Pulmicort) DPI: 400–2400 µg/day, divided bid Nebules: 1–2 mg bid DPI: 200-400 μg/day, divided bid (not indicated for children < 6 years) Nebules: 0.25-0.5 mg bid (for children 3 months to 12 years)
Ciclesonide (Alvesco) MDI: 100–800 µg/day MDI: 100–200 µg/day (not indicated for children < 6 years)
Fluticasone (Flovent HFA, Flovent Diskus) MDI/DPI: 100–500 µg bid MDI/DPI: 50–200 µg bid (for children 4-16 years) MDI: 100 µg bid (via a pediatric spacer device with a face mask) (for children 12 months to 4 years)
Combination ICS/LABA inhalers
Budesonide/formoterol (Symbicort) DPI (maintenance): 100/6 µg or 200/6 µg, 1–2 puffs od or bid; max 4 puffs/day DPI (maintenance and reliever): 100/6 µg or 200/6 µg, 1–2 puffs bid or 2 puffs od; plus 1 puff as needed for relief of symptoms (no more than 6 puffs on any single occasion); max 8 puffs/day Not indicated for children under 12 years of age
Fluticasone/salmeterol (Advair MDI, Advair Diskus) MDI: 125/25 µg or 250/25 µg, 2 puffs bid Diskus: 100/50 µg, 250/50 µg or 500/50 µg: 1 puff bid MDI: not indicated for children under 12 years of age Diskus: 100/50 µg, 1 puff bid (not indicated for children <4 years)
Mometasone/ formoterol (Zenhale) For patients previously treated with: – Low-dose ICS: 50/5 µg, 2 puffs bid – Medium-dose ICS: 100/5 µg, 2 puffs bid – High-dose ICS: 200/5 µg, 2 puffs bid Not indicated for children under 12 years of age
LTRAs
Montelukast (Singulair) 10 mg tablet od (taken in the evenings) 5 mg chewable tablet od (taken in the evenings) (for children 6-14 years) 4 mg chewable tablet od or 4 mg packet of granules od (taken in the evenings) (for children 2-5 years of age)
Zafirlukast (Accolate) 20 mg tablet bid, at least 1 h before or 2 h after meals Not indicated for children under 12 years of age
Anti-IgE therapy
Omalizumab (Xolair) 150–375 mg sc every 2–4 weeks (based on patient’s weight and pre-treatment serum IgE level) Not indicated for children under 12 years of age
  1. ICS: inhaled corticosteroid; MDI: metered dose inhaler; DPI: dry powder inhaler; LTRA: leukotriene receptor antagonists; IgE: immunoglobulin E; od: once daily; bid: twice daily; sc: subcutaneously